Fig 1: Representative images showing RGS5 (a marker for tumor vascular normalization) immunohistochemistry staining in Lewis lung cancer tumors after treatment with rh-ES or NS for days 2, 4, 6 and 9. The positive RGS5 signals were located in the cytoplasm and had a color of light yellow to brown. Magnification, ×400. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; NS, normal saline.
Fig 2: ELISA assay demonstrating RGS5 protein levels in rh-ES and NS LLC tumors. RGS5 protein levels at days 4 and 6 of rh-ES-treated LLC tumors presented a significant reduction compared with saline-treated LLC tumors, whilst there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS.RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; LLC, Lewis lung cancer; NS, normal saline.
Fig 3: Quantification of RGS5 immunoreactivity. The expression of RGS5 at days 4 and 6of rh-ES-treated Lewis lung cancer tumors demonstrated a significant reduction compared with NS LLC tumors, whilst there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; NS, normal saline.
Fig 4: Reverse transcription-quantitative polymerase chain reaction demonstrating RGS5 mRNA levels in rh-ES and NSLLC tumors. RGS5 mRNA levels at days 4 and 6 of rh-ES-treated LLC tumors presented a significant reduction compared with saline-treated LLC tumors while there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; LLC, Lewis lung cancer; NS, normal saline.
Fig 5: Homogeneous expansion of pericytes and their potential trans-differentiation relationship with fibroblasts. (a) Intergroup comparison of RGS5 immunofluorescence staining. (b) UMAP visualization of pericytes reclustered into 11 subclusters by unsupervised clustering. (c) Stacked percentage plot showing differences in the proportions of pericyte subclusters between NS and HTS. (d) Pseudotime trajectories from joint analysis of fibroblasts and pericytes, coloured by cell type (left). (e) Pseudotime trajectory of the merged dataset, coloured by group and cell type, suggesting a potential trans-differentiation relationship between pericytes and Fib_5. (f) Centrality score heatmaps of selected significant signalling pathways identified by CellChat. * P < 0.05. UMAP Uniform Manifold Approximation and Projection, NS normal skin, HTS hypertrophic scars
Supplier Page from Abcam for Anti-RGS5 antibody